<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03148717</url>
  </required_header>
  <id_info>
    <org_study_id>AS1380</org_study_id>
    <nct_id>NCT03148717</nct_id>
  </id_info>
  <brief_title>Preoperative vs. Postoperative Rectal Misoprostol in Cesarean Section</brief_title>
  <official_title>Preoperative vs. Postoperative Rectal Misoprostol in Cesarean Section: A Randomized, Double Blind Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective double-blind placebo-controlled randomized clinical trial will be conducted
      at Ain-Shams University Maternity Hospital from April 2017 till December 2017. Group 1 women,
      candidates for cesarean section, will receive preoperative rectal 400 microgram of
      misoprostol, and Group 2 women will receive postoperative rectal 400 microgram of
      misoprostol.

      2017. 120 women candidate foe elective cesarean section will receive preoperative sublingual
      400 microgram of misoprostol, and another 120 women will receive postoperative sublingual 400
      microgram of misoprostol.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 10, 2017</start_date>
  <completion_date type="Actual">March 20, 2018</completion_date>
  <primary_completion_date type="Actual">March 2, 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neonatal outcome</measure>
    <time_frame>5 minutes</time_frame>
    <description>measured by APGAR score at 5 minutes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>NICU admission</measure>
    <time_frame>24 hours</time_frame>
    <description>Number of neonates admitted to NICU within 24 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>amount of blood loss</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postpartum hemorrhage</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for extra uterotonics</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>APGAR score at 1 minute</measure>
    <time_frame>1 minute</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">300</enrollment>
  <condition>Neonatal Outcome</condition>
  <arm_group>
    <arm_group_label>Preoperative</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group no.1 will receive preoperative rectal 400 microgram of misoprostol (Sigma) &quot;2 tablets&quot; and postoperative rectal placebo&quot;2 tablets&quot;.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Postoperative</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group no.2 will receive preoperative rectal placebo &quot;2 tablets&quot; and postoperative rectal 400 microgram of misoprostol (Sigma) &quot; 2 tablets&quot; .</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Misoprostol</intervention_name>
    <description>Cytotec</description>
    <arm_group_label>Preoperative</arm_group_label>
    <arm_group_label>Postoperative</arm_group_label>
    <other_name>Mesotac</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablet similar in shape, odour and consistency to misoprostol tablet.</description>
    <arm_group_label>Preoperative</arm_group_label>
    <arm_group_label>Postoperative</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients candidate for cesarean section.

          2. Full term pregnancies (GA 37- 42 Wks).

          3. Age (18-40 yrs).

          4. body mass index (BMI) (20-30(Kg/m2 .

        Exclusion Criteia:

          1. Contraindication to spinal anesthesia.

          2. Blood dyscrasias.

          3. Large fibroids.

          4. Contraindications to prostaglandin therapy (e.g. history of severe bronchial asthma or
             allergy to misoprostol.

          5. Emergency CS such as fetal distress

          6. Extreme of BMI (&lt;20 or &gt;30 Kg/m2 ).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ain Shams University</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 29, 2017</study_first_submitted>
  <study_first_submitted_qc>May 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2017</study_first_posted>
  <last_update_submitted>March 21, 2018</last_update_submitted>
  <last_update_submitted_qc>March 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Mohamed S Sweed, MD</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Misoprostol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

